#Japan #Tokyo #Innovation Award #PharmaEssentia #TECH-Tokyo

PharmaEssentia Innovation Award Launch

On March 27, 2026, PharmaEssentia Corporation, a leading global biopharmaceutical company based in Taipei, Taiwan, announced the creation of the "PharmaEssentia Innovation Award". This initiative aims to discover and support startup teams in the biotechnology and healthcare sectors that hold commercial potential in the global market. The award will be executed in collaboration with TECH-Tokyo, a prominent innovation hub in Japan. Both companies will simultaneously recruit biomedical startups in Taiwan and Japan, promoting collaboration between the two regions and accelerating the deployment of groundbreaking biomedicine technologies and products onto the global stage.

The application for the award has opened today, with a grand prize of $100,000, part of a total prize pool of $200,000. PharmaEssentia intends for this award not to be merely a provision of research funds but to promote exchanges of cutting-edge technology through resource provision from the industry and knowledge sharing, accelerating innovations led by startup teams into clinical development and global commercialization. As the global pharmaceutical industry evolves rapidly, innovation in biotechnology extends beyond the confines of R&D within single entities, generating new opportunities through interdisciplinary and cross-border collaboration networks.

Under the philosophy of "building connections, enabling collaboration, and fostering innovation," the PharmaEssentia Innovation Award seeks to establish a cross-border platform that bridges academic research capabilities, the vigor of startups, and international industry resources. This initiative aims to facilitate interactions, enhance value, and lay the groundwork for future strategic collaborations.

Focusing on strategic fields closely linked to PharmaEssentia's core R&D directions and global business expansion, the award welcomes applications from startup teams that have the potential to introduce innovative therapies. Areas of interest include innovative drug research and development for blood diseases, cancers, rare diseases, and autoimmune disorders, as well as drug discovery and development platforms powered by artificial intelligence (AI) and machine learning (ML), along with ex vivo or in vivo cell therapy technology platforms.

The judging panel will comprise leading experts from Harvard University in the United States, alongside leaders from the industry and research institutions in Taiwan and Japan. Judges possess expertise in hematology, oncology, immunology, and bring a wealth of industry experience and outstanding academic achievements, ensuring a balanced evaluation that considers scientific innovation, clinical applicability, and potential for global market deployment.

Through the inaugural PharmaEssentia Innovation Award, PharmaEssentia expects to collaborate with TECH-Tokyo to promote innovative research and development, academic exchanges, and industrial applications between Taiwan and Japan, as well as to create opportunities for long-term and substantive strategic partnerships. Future events will invite more startup teams from additional countries to expand the program, continuing to provide innovative treatment options for patients worldwide while enhancing the international recognition and influence of Taiwan's biotechnology industry.

For more details on how to apply for the PharmaEssentia Innovation Award, visit: PharmaEssentia Innovation Award 2026

Contact Information

PharmaEssentia Corporation
Annie Lin
Email: [email protected]

TECH Tokyo LLC
PharmaEssentia Innovation Award Secretariat
Email: [email protected]

About PharmaEssentia Japan

Founded in 2017, PharmaEssentia Japan is the Japanese subsidiary of PharmaEssentia Corporation, headquartered in Taipei. Despite rapid advancements in drug development technology leading to many groundbreaking treatments, certain disease areas still lack achievement of "real therapeutic goals." PharmaEssentia Japan aims to meet these unmet medical needs using its core technology, the "site-selective monopegylation technology" platform, particularly focusing on the field of blood disorders. For more details, visit: PharmaEssentia Japan

About TECH-Tokyo

Technology Exchange and Collaboration Hub in Tokyo (TECH-Tokyo G.K.) aims to connect distinguished university faculty, researchers, entrepreneurs, and Japanese businesses, investors, and academic institutions. Through a variety of programs including presentations, workshops, networking events, and contests, TECH-Tokyo fosters partnerships through licensing, collaboration, and venture funding. For more details, visit: TECH-Tokyo

Company Overview

PharmaEssentia Japan Ltd.
CEO: Katsuya Yonetsu
Location: 12th floor, Akasaka Center Building, 1-3-13 Motoakasaka, Minato, Tokyo, 107-0051
Phone: 03-6910-5103
Fax: 03-6910-5109
URL: PharmaEssentia Japan

TECH-Tokyo LLC
Executive Director: Cortell Albert Jorge
Location: 37th floor, Shibuya Sakura Stage SHIBUYA Tower, 1-1 Sakuragaokacho, Shibuya, Tokyo, 150-0031
URL: TECH-Tokyo